瑋俊生物科技(00660.HK)擬根據特定授權發行6700萬港元可換股債
格隆匯 7 月 28日丨瑋俊生物科技(00660.HK)發佈公告,2020年7月28日,公司與認購人黃志勇先生訂立該認購協議,據此,公司有條件同意發行本金總額為6700萬港元的可換股債券。
可換股債券附帶換股權,可按換股價每股換股股份0.022港元(可予調整)轉換為換股股份,以作為債務清償。該認購人根據該認購協議應付的認購款項將透過抵銷公司應付予該認購人及╱或其聯繫人的該貸款(預期於完成日期將合共為6700萬港元)項下的未償還本金額及應計利息而償付。
假設換股權按換股價悉數行使,則在若干換股限制的規限下可根據該認購協議而向該認購人配發及發行合共約30.45億股新股份(即換股股份)。換股股份相當於該公告日期全部已發行股份數目約18.36%以及經向該名認購人配發及發行換股股份擴大的全部已發行股份數目約15.51%,當中假設於該公告日期至換股權獲悉數行使的日期的股份總數並無其他變動。換股股份將根據將於股東特別大會上徵求股東批准的特定授權而配發及發行。
公司不會申請讓可換股債券於聯交所上市。公司將向聯交所上市委員會申請批准換股股份上市及買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.